Cara Therapeutics Inc
Most Recent
Key Cannabis Sector Updates: Analyst Ratings and Earnings
Last week, Emerald Health Therapeutics (EMH) closed with losses of 9.4%.
Cannabis Stocks Had a Mixed Performance Last Week
Cannabis ETFs traded on a largely negative note last week.
Ups and Downs in the Cannabis Space Last Week
The cannabis space was mostly positive last week. The Horizons Marijuana Life Sciences ETF (HMMJ) and the ETFMG Alternate Harvest ETF (MJ) gained 5.2% and 4.2%, respectively.
Cannabis Updates: New Listings, Price Action, and Ratings
The cannabis sector showed some weakness last week, and the Horizons Marijuana Life Sciences ETF (HMMJ) lost 3.0% while the ETFMG Alternate Harvest ETF (MJ) lost 3.4%.
Charlotte’s Web Holdings Reports Record Harvest in 2018
Charlotte’s Web Holdings (CWBHF) posted a record harvest of 675,000 pounds last year.
Analyzing CARA, INSY, and GWPH’s Earnings Trends
GW Pharmaceuticals’ (GWPH) net income was -$295.2 million in fiscal 2018—compared to -$170.5 million in fiscal 2017.
CARA, INSY, and GWPH: Analysts’ Recommendations in January
On January 28, Cara Therapeutics’ (CARA) stock price closed at $14.82, which is an ~4.02% discount compared to its previous close.
Cara Therapeutics: Earnings Trends and Recent Developments
In the first nine months of 2018, Cara Therapeutics (CARA) reported a net income and EPS of -$53.4 million and -$1.54, respectively.
Cara Therapeutics: A Financial Overview in January
In the first nine months of 2018, Cara Therapeutics (CARA) generated revenues of $7.9 million.
Cara Therapeutics Has Risen ~18% in January
Cara Therapeutics’ (CARA) stock price reached $15.35 on January 18—compared to $13.00 when the market closed on December 31.
How Is INSYS Therapeutics Financially Positioned in January?
In the first nine months of 2018, INSYS Therapeutics’ net revenues declined ~40% YoY to reach $109.2 million from $65.7 million.
A Look into GW Pharmaceuticals’ Revenue Trends
In the fourth quarter of fiscal 2018, GW Pharmaceuticals (GWPH) generated revenues of $2.42 million compared to $2.45 million in the same period the prior year.
What’s Auxly Cannabis’ MidStream Strategy in 2018?
On August 31, Auxly Cannabis announced the completion of the acquisition of KGK Science for a total consideration of $12.3 million.
Curaleaf Opens Medical Marijuana Dispensary in Tallahassee
On November 16, Curaleaf Holdings announced that the company opened Tallahassee’s largest medical marijuana dispensary.
MedMen’s Territory Expansion: The Recent Agreements
MedMen (MMNFF) has entered into agreements with different companies to expand its footprint. We outline a few of the recent agreements below.
Analyzing 22nd Century Group’s Year-to-Date Performance
Analysts expect 22nd Century Group to report revenue of $23.3 million in 2018, a 40.3% rise compared to $16.6 million in 2017.
A Closer Look at Insys Therapeutics’ Performance Year-to-Date
Insys Therapeutics (INSY) is among the specialty pharmaceutical companies that focus on developing cannabinoids and sprays.
How Marijuana-Focused Biotech Companies Have Performed in 2018
In this series, we’ll discuss analysts’ estimates, recommendations, and revenue estimates for marijuana biotechnology companies.
Cara Therapeutics: Performance and Estimates for Q3
Cara Therapeutics reported revenues of $2.87 million in the second quarter compared to no revenues in the second quarter of 2017.
Marijuana-Focused Biotech Companies in Q3: Are They Performing?
In this series, we’ll look at biotechnology companies focused on marijuana-based products and how they performed in the third quarter.
How Is Insys Therapeutics Positioned in H2 2018?
Insys Therapeutics generated total revenues of $23.46 million in the second quarter of 2018 as compared to $42.58 million in the second quarter of 2017.
Why Heron Therapeutics Rose 33% in Pre-Market Trading Today
Heron Therapeutics (HRTX) stock surged after the company announced it had received breakthrough designation from the FDA for its postoperative pain management drug, HTX-011.
Comparing Cara Therapeutics’ Financial Performance
Financial performance In 3Q17, Cara Therapeutics (CARA) incurred $9.6 million in research and development expenses, compared with $9.1 million in 3Q16. This fall in expenses was due to a $3.1 million decrease in expenses for oral CR845’s Phase 2B clinical trial, and partially offset by increased expenses for its intravenous CR845 safety study. Meanwhile, the company’s general and administrative expenses rose from […]
Cara Therapeutics’ Collaboration Agreements
Oral CR845 for treating chronic kidney disease–associated pruritus In July 2017, Cara Therapeutics (CARA) announced the results from a Phase 1 safety and pharmacokinetics study of oral CR845 in patients with chronic kidney disease (or CKD) undergoing hemodialysis. The results showed that the four dosage strengths evaluated in the study were well tolerated. In October […]
A Look at Cara Therapeutics’ Intravenous CR845
Intravenous CR845 for pruritus Pruritus is associated with chronic conditions such as chronic kidney disease (or CKD), atopic dermatitis, eczema, cholestatic liver disease, and psoriasis. Based on CR845’s effectiveness on the peripheral nervous system and immune cells, as well as its anti-pruritic potency, Cara Therapeutics (CARA) believes the drug has the potential to treat pruritus […]
Analysts’ Recommendations for Cara Therapeutics in January 2018
Cara Therapeutics (CARA) is a clinical-stage biopharmaceutical company focused on developing and commercializing chemical entities designed to alleviate pain and pruritus.
IBB’s Top Performers: PETX Gains on Its First FDA Approval
IBB’s top performers for March 21, 2016, were Cara Therapeutics (CARA), OvaScience (OVAS), Sarepta Therapeutics (SRPT), and Aratana Therapeutics (PETX).
